McGrath Lynne Fahey
SEC Form 4 insider trading activity
McGrath Lynne Fahey has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2025. 1 of those filings fall inside the rolling window. Most recent filing: Oct 24, 2025.
On the most recent filing, McGrath Lynne Fahey is listed as Director at Alzamend Neuro, Inc. Inside the rolling window, McGrath Lynne Fahey reported no open-market purchases and 1 open-market sale totaling $69 in ALZN.
Companies traded
Other insiders at ALZN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$69
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has McGrath Lynne Fahey made?
McGrath Lynne Fahey has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2025.
Which companies does McGrath Lynne Fahey trade?
McGrath Lynne Fahey has filed SEC Form 4 disclosures for 1 company, including ALZN.
When was McGrath Lynne Fahey's most recent SEC Form 4 filing?
McGrath Lynne Fahey's most recent SEC Form 4 filing on Tracefour is dated Oct 24, 2025.
What is McGrath Lynne Fahey's total buy and sell value in the current window?
Inside the rolling retention window, McGrath Lynne Fahey bought $0 and sold $69 based on SEC Form 4 filings.
What was McGrath Lynne Fahey's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 30 ALZN shares on 2025-10-23, worth $69, per SEC Form 4 filings.